Table 2 Clinicopathological characteristics of patients in MGRS group

Male [n (%)]

17 (68.0)

4 (57.1)

2 (66.7)

2 (38.1)

Age (year)

58.0  ±  7.7

53.3  ±  16.4

69.7  ±  8.4

56.4  ±  7.5

Renal disease duration before renal biopsy (months)

10.0  ±  10.8

7.8  ±  7.0

22.0  ±  22.7

13.7  ±  10.3

Hematuria [n (%)]

2 (23)^a,c

6 (85.7)

1 (33.3)

3 (60.0)

Proteinuria (g/24 h)

3.8  ±  2.3

7.0  ±  2.9^a,d,e

2.0  ±  1.6

2.1  ±  1.5

Albumin (g/L)

25.8  ±  5.8

25.4  ±  3.9

36.6  ±  1.7^b,d

31.1  ±  9.7

Hemoglobin (g/L)

123.4  ±  16.5^a,b,c

91.1  ±  12.5

93.0  ±  28.2

104.6  ±  16.5

SCr (μmol/L)

134.2  ±  216.8

243.3  ±  197.3

386.3  ±  221.0^b,f

78.6  ±  33.1^e

eGFR (mL/min/1.73m²)

81.7  ±  37.6

29.0  ±  17.1^a,e

18.4  ±  10.7 ^b,f

80.1  ±  30.4

Low serum C3 [n (%)]

4 (16.0)^c

3 (42.9)

2 (66.7)

5 (100)

Abnormal serum κ/λ ratio [n (%)]

13 (52.0)

3 (42.9)

2 (66.7)

0 (0)

Abnormal urine κ/λ ratio [n (%)]

14 (60.9)

1 (14.3)

2 (66.7)

0 (0)

Abnormal sIFE [n (%)]

16 (66.7)

5 (71.4)

2 (66.7)

1 (20)

Abnormal uIFE [n (%)]

17 (77.3)

3 (75)

2 (100)

1 (50)

κ (sIFE, [n (%)])

3 (20.0)^a

4 (80)

1 (50)

0 (0)

κ (uIFE, [n (%)])

3 (18.8)

1 (33.3)

1 (50.0)

0 (0)

Renal monotypic κ [n (%)]

4 (16.0)^c

5 (71.4)

2 (66.7)

4 (80)

Global glomerulosclerosis (%)

14.4  ±  16.4

17.4  ±  22.8

42.3  ±  13.7^b,d,f

12.6  ±  13.8

Segmental glomerulosclerosis (%)

0

3.1  ±  8.3

0

2  ±  4.5

Crescents (%)

0

18.0  ±  32.2^a

0

8.2  ±  6.8

IFTA

1.04  ±  0.69^a

1.86  ±  0.69^e

3.0  ±  0.0^b,d,f

1.0  ±  0.0

Interstitial inflammation

0.79  ±  0.66^a,b

2.14  ±  0.69

2.33  ±  0.58

1.40  ±  0.89

Podocyte effacement (%)

2.6  ±  0.6

2.6  ±  0.8

2.3  ±  0.6

2.4  ±  0.9